LN Peptides
Finnrick has tested 34 samples from LN Peptides across 5 products.
Take Action
Request Full Data Access to the Finnrick database of peptide tests.
Products
| Tests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Product | Rating | Count | Avg | Min | Max | Oldest | Most Recent | |
| Retatrutide | 10 | 17 Nov 2025 | 4 Jun 2026 | |||||
| Tirzepatide | 14 | 3 Oct 2025 | 28 Apr 2026 | |||||
| Tesamorelin | 8 | 21 Oct 2025 | 6 Mar 2026 | |||||
| Ipamorelin | 1 | 25 Sep 2025 | 25 Sep 2025 | |||||
| Mazdutide | 1 | 9 Oct 2025 | 9 Oct 2025 | |||||
The LN Peptides samples tested by Finnrick were either acquired by Finnrick directly, or submitted by the public.
Customer Reviews
These indicators of customer satisfaction are based on reports submitted by the public through the Finnrick testing program, and are not verified.
Based on 10 overall satisfaction reports
People who submitted test requests to Finnrick gave LN Peptides an average satisfaction rating of 4.6 out of 5 across 10 reports associated with samples received and tested by Finnrick.
Most recent LN Peptides tests
Samples are tested in commercial labs
tests
products
Scores
First
Last
| Quantity | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Product | Certificate | Test Score | Label | Batch | Tested | Difference | Purity | Endotoxins | Batch ID | Container | Tested At | Sent By |
| 4 Jun 2026 | Retatrutide | View | 10mg | (no batch claim) | 10.1mg | +1.0% | 99.70% | n/a | April 15, 2026 | No label / Silver crimp / Clear Pink cap | Lab G | Public | |
| 1 Jun 2026 | Retatrutide | View | 20mg | (no batch claim) | 12.1mg | -39.5% | 99.90% | below LOQ | (no batch ID) | No label / Red crimp / Blue cap | Lab E | Public | |
| 13 May 2026 | Retatrutide | View | 10mg | (no batch claim) | 9.95mg | -0.5% | 99.90% | n/a | Rt10 purple cap | White label / Silver crimp / Clear Violet cap | Lab E | Public | |
| 28 Apr 2026 | Tirzepatide | View | 60mg | 59.0mg | 12.3mg | -79.2% | 99.50% | low | Translucent yellow top | No Label / Silver Crimp / Yellow Cap | Lab E | Public | |
| 6 Mar 2026 | Tesamorelin | View | 10mg | (no batch claim) | 8.43mg | -15.7% | 99.90% | n/a | (no batch ID) | Silver Label / Silver Crimp / Clear Blue Cap | Lab E | Public | |
| 6 Mar 2026 | Tesamorelin | View | 10mg | (no batch claim) | 8.01mg | -19.9% | 99.90% | n/a | (no batch ID) | White Label / Silver Crimp / Clear Blue Cap | Lab E | Public | |
| 2 Mar 2026 | Tesamorelin | View | 10mg | (no batch claim) | 10.3mg | +3.0% | 98.47% | below LOQ | TES10012026LN | No Label / Silver Crimp / White Cap | Lab E | Public | |
Corrections
- 12 Dec 2025:
- Submitter originally registered vendor as "Diju Peptides Wellness" by mistake during sample registration, the test result has been adjusted to to "LN Peptides".
- 12 Dec 2025:
- Submitter originally registered vendor as "Diju Peptides Wellness" by mistake during sample registration, the test result has been adjusted to to "LN Peptides".
About LN Peptides Test Results From Finnrick
LN Peptides is a peptide vendor with multiple products tracked in the independent testing dataset collected by Finnrick. This page compiles recent, batch-level test results across 5 products and 34 tests, including scores, test dates, batch IDs, and lab details. This enables you to compare quality over time, not just marketing claims.
Each tested sample receives a 0–10 score, with 10 being the best possible value. It is the total of three components: purity (0–4 points), quantity accuracy vs. the label or batch claim (0–4 points), and batch information quality (0–2 points).
When several test results are available for a product and vendor pair, you’ll also find a Finnrick Rating (A–E, where A is best and E is worst, X if an insufficient number of tests is available, or F in rare cases of documented and widespread fraud) and customer satisfaction reports with sub-scores that provide additional context. Use the table above to review purity, quantity accuracy, consistency between batches, and any notable outliers surfaced in Finnrick testing data.
LN Peptides Testing Activity & Score Summary
In the past 30 days, Finnrick has published 2 new test results for LN Peptides, and 4 in the past three months. The overall dataset includes 34 tested samples with an average score of 6.1/10 across all products.
Across 34 identity-tested samples, 97% were confirmed to contain the expected peptide (identity pass rate). Among those that passed, median purity was 99.8%. Approximately 94% of passing samples tested at or above 98% purity.
Here is a closer look at the most frequently tested products (top 3):
- Retatrutide (10 tests, 100% identity pass, median purity 99.8%) — Test scores are highly variable, ranging from 4.8 to 10.0 (average 7.1/10), suggesting significant batch-to-batch differences.
- Tirzepatide (14 tests, 100% identity pass, median purity 99.8%) — Test scores are highly variable, ranging from 4.8 to 10.0 (average 6.7/10), suggesting significant batch-to-batch differences.
- Tesamorelin (8 tests, 88% identity pass, median purity 98.9%) — Test scores are highly variable, ranging from 0.0 to 7.5 (average 3.9/10), suggesting significant batch-to-batch differences.